| Tysabri (natalizumab) / Biogen, Royalty |
2007-007394-22: The role of white and grey matter and meningeal inflammation in multiple sclerosis (MS) and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (PET) scanning |
|
|
| Ongoing | 4 | 10 | Europe | Tysabri, Tysabri, Tysabri | Imperial College London | Multiple Sclerosis | | | | |
| Ongoing | 4 | 60 | Europe | beetainterferoni -1a, Fingolimodi, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada | Turku University Hospital, Novartis Pharma | Multiple sclerosis MS-tauti | | | | |
2016-000345-31: Reduce the number of natalizumab infusions in patients with multiple sclerosis Verminderen van het aantal giften van natalizumab bij patiënten met multiple sclerose |
|
|
| Ongoing | 4 | 60 | Europe | natalizumab, Solution for infusion, tysabri | VU medical center, de Hersenstichting | multiple sclerosis multiple sclerose, MS MS, Diseases [C] - Nervous System Diseases [C10] | | | | |
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros. |
|
|
| Ongoing | 4 | 150 | Europe | Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio | Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet | Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10] | | | | |
2013-002433-38: Essai visant à tester la différence d’efficacité du Natalizumab, versus le fingolimod, 2 médicaments pour le traitement de la sclérose en plaques |
|
|
| Not yet recruiting | 4 | 500 | Europe | natalizumab, fingolimod, Concentrate for solution for infusion, Capsule, TYSABRI, GILENYA | CHU de Toulouse, FP7 Health Innovation-1 | Sclérose en plaques, Sclérose en plaques, Diseases [C] - Nervous System Diseases [C10] | | | | |
2019-002566-13: Personalizing the treatment with natalizumab in patients with multiple sclerosis |
|
|
| Not yet recruiting | 4 | 300 | Europe | natalizumab, Solution for infusion, Tysabri | Amsterdam University Medical Center, Innovatiefonds Zorgverzekeraars, Stichting MS Research, de Hersenstichting | Relapsing remitting multiple sclerosis, Multiple sclerosis (MS), Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT04048577: A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab |
|
|
| Recruiting | 4 | 10 | US | Dosing Interruption of Natalizumab, Dosing Interruption of Tysabri | Berkovich, Regina MD, PhD Inc., Biogen, Cedars-Sinai Medical Center | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | 11/21 | 12/21 | | |
| Completed | 4 | 30 | US | Natalizumab | State University of New York at Buffalo | Multiple Sclerosis | 12/23 | 12/23 | | |
NCT05532163: A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) |
|
|
| Terminated | 4 | 1 | Europe | Natalizumab, Tysabri, BG00002 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 10/23 | 10/23 | | |
| Recruiting | 4 | 56 | Europe | Methylprednisolone, Placebo, natalizumab (NTZ), fingolimob (FTY) | University Hospital, Clermont-Ferrand | Multiple Sclerosis | 06/24 | 07/24 | | |
NCT04178005: Cladribine Tablets After Treatment With Natalizumab (CLADRINA) |
|
|
| Active, not recruiting | 4 | 40 | US | Cladribine, Mavenclad | University of Texas Southwestern Medical Center, EMD Serono | Multiple Sclerosis | 08/24 | 12/26 | | |
| Terminated | 4 | 1 | US | Natalizumab 300 MG in 15 ML Injection | Vanderbilt University Medical Center, Biogen | Multiple Sclerosis | 04/23 | 04/23 | | |
SUPERNEXT, NCT04225312: Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis |
|
|
| Enrolling by invitation | 4 | 300 | Europe | Personalized extended interval dosing of natalizumab, EID, Standard interval dosing, SID | Amsterdam UMC, location VUmc, Stichting MS Research, Innovatiefonds Zorgverzekeraars, Stichting Treatmeds | Relapsing Remitting Multiple Sclerosis | 03/25 | 03/25 | | |
| Active, not recruiting | 4 | 800 | Europe, US | Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod) | The Cleveland Clinic, University of Nottingham | Multiple Sclerosis, Relapsing-Remitting | 07/27 | 09/30 | | |
ACTRN12605000769684: An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 or C-1802 and a Dosing Suspension Safety Evaluation |
|
|
| Not yet recruiting | 3/4 | 900 | | | Biogen Idec, Biogen Idec, Elan Pharmaceuticals | Multiple Sclerosis | | | | |
ACTRN12616000617460: What is the safety and effectiveness, acceptability and cost of flexible delivery of natalizumab (Tysabri (Registered Trademark)) by nurses for people with multiple sclerosis? |
|
|
| Active, not recruiting | 3 | 50 | | | Dr Janakan Ravindran, Biogen Australia and New Zealand | relapsing-remitting multiple sclerosis (MS) | | | | |
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive |
|
|
| Not yet recruiting | 3 | 250 | Europe | AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion | CHU de Rennes, CHU de Rennes | Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10] | | | | |
NOVA, NCT03689972 / 2018-002145-11: A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration |
|
|
| Completed | 3 | 585 | Europe, Canada, US, RoW | Natalizumab, BG00002 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 01/23 | 07/23 | | |
NCT05265728: A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis |
|
|
| Terminated | 3 | 21 | Japan | Natalizumab, BG00002 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 01/24 | 05/24 | | |
BEAT-MS, NCT04047628: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis |
|
|
| Recruiting | 3 | 156 | US | Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Best Available Therapy (BAT), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), rituximab (Rituxan®), cladribine (Mavenclad®), ofatumumab (Kesimpta®), ublituximab (BRIUMVI™) | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Blood and Marrow Transplant Clinical Trials Network, PPD, Rho Federal Systems Division, Inc. | Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | 10/26 | 10/29 | | |
| Recruiting | 2/3 | 5 | Europe | Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT) | Sheffield Teaching Hospitals NHS Foundation Trust | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | 12/21 | 12/21 | | |
2010-023560-40: Blood stem cell transplantation for patients with relapsiong-remitting multiple sclerosis, in whom standard treatment has failed. Blodstamcellstransplantation för patienter med skovvis förlöpande MS (multipel sklerosis), där standardbehandling givit otillräcklig effekt. |
|
|
| Ongoing | 2 | 120 | Europe | , Powder for solution for injection, Powder for infusion*, Solution for injection, Powder and solvent for dispersion for injection, Tysabri, Sendoxan, Thymoglobuline, Neupogen, Solu-Medrol | Uppsala l�ns landsting | Relapsing-remitting multiple sclerosis | | | | |
2014-000675-13: Natalizumab (Tysabri®) for the treatment of anti-Hu associated paraneoplastic neurological syndromes Natalizumab (Tysabri®) voor de behandeling van paraneoplastische neurologische syndromen met anti-Hu antistoffen |
|
|
| Ongoing | 2 | 20 | Europe | Tysabri (natalizumab), Concentrate and solvent for solution for infusion, Tysabri | Erasmus University Medical Center, Biogen Idec International B.V. | Anti-Hu associated paraneoplastic neurological syndromes, Anti-Hu associated paraneoplastic neurological syndromes, Diseases [C] - Immune System Diseases [C20] | | | | |
2019-003127-38: Research on the effect of add-on high dosage simvastatin treatment on progression in MS patients treated with ocrelizumab and natalizumab. Onderzoek naar het effect van het toevoegen van hoge dosis simvastatine op progressie van MS patiënten die behandeld worden met ocrelizumab en natalizumab. |
|
|
| Not yet recruiting | 2 | 100 | Europe | Simvastatin, Tablet | VUmc Neurology Department, Stichting MS Research | Multiple sclerosis Multiple sclerose, Multiple sclerosis Multiple sclerose, Diseases [C] - Nervous System Diseases [C10] | | | | |
2022-002654-95: No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis Nessuna evidenza di attività della malattia dopo trapianto autologo di cellule staminali ematopoietiche nella Sclerosi Multipla aggressiva |
|
|
| Not yet recruiting | 2 | 90 | Europe | OCREVUS, Kesimpta 20 mg soluzione iniettabile, TYSABRI, LEMTRADA, Non disponibile, Solution for injection, Powder for concentrate for solution for infusion, Powder and solvent for concentrate for solution for infusion, Concentrate for solution for infusion, Powder and solvent for solution for injection, Powder for solution for injection, OCREVUS, Kesimpta, TYSABRI, LEMTRADA | FONDAZIONE ITALIANA SCLEROSI MULTIPLA ONLUS, Fondazione Italiana Sclerosi Multipla | Relapsing Remitting Multiple Sclerosis Sclerosi multipla recidivante remittente, A type of MS where you have relapses (symptoms getting worse) followed by recovery (that's when it's “remitting”) Forma di Sclerosi Multipla nella quale in cui si hanno ricadute (sintomi che peggiorano) seguite da guarigione (le remissioni)., Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT05418010: Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS) |
|
|
| Recruiting | 2 | 40 | Europe | Tysabri Injectable Product, Natalizumab, Placebo | Queen Mary University of London, Biogen, UCL Queen Square Institute of Neurology, Moorfields Eye Hospital NHS Foundation Trust, Barts & The London NHS Trust | Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination | 05/24 | 05/24 | | |
2008-005871-92: En fas 1 studie av effekt av Tysabri (natalizumab), en IgG4 humaniserad monoklonal antikropp specifik mot VLA-4 (integrin alfa-4), administrerad som infusion 1 gång/månad under 3 månader hos patienter med kronisk idiopatisk trombocytopen purpura (ITP). |
|
|
| Ongoing | 1/2 | 20 | Europe | Tysabri, Tysabri, Tysabri | Sahlgrenska University Hospital | Chronic idiopathic thrombocytopenic purpura (ITP) | | | | |
NCT03811886: Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma |
|
|
| Recruiting | 1/2 | 20 | US | Natalizumab, Tysabri | Case Comprehensive Cancer Center | Pulmonary Metastatic Osteosarcoma (pOS) | 12/25 | 10/26 | | |
| Completed | 1 | 66 | Europe | Natalizumab, Tysabri, Placebo: normal saline | King's College London, South London and Maudsley NHS Foundation Trust | Schizophrenia | 06/23 | 08/23 | | |
NCT05618301: Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) |
|
|
| Recruiting | 1 | 10 | US | Motixafortide, BL-8040, Natalizumab, Tysabri, Leukapheresis | Washington University School of Medicine, BioLineRx, Ltd., Biogen | Sickle Cell Disease | 12/25 | 12/25 | | |
| Completed | N/A | 17478 | RoW | interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab | IMPULS Endowment Fund | Multiple Sclerosis | 12/21 | 12/21 | | |
NCT04964700: Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab |
|
|
| Active, not recruiting | N/A | 42 | US | Natalizumab, Tysabri | Multiple Sclerosis Center of Northeastern New York | Multiple Sclerosis | 04/22 | 06/22 | | |
| Active, not recruiting | N/A | 3526 | Europe | Rituximab, Natalizumab, Fingolimod, Alemtuzumab, Interferon-beta, Glatiramer acetate, Dimethyl Fumarate | Karolinska Institutet, Patient-Centered Outcomes Research Institute, Kaiser Foundation Research Institute | Relapsing-remitting Multiple Sclerosis | 12/22 | 12/22 | | |
| Completed | N/A | 39 | Europe | ocrelizumab, Ocrevus, natalizumab, Tysabri, ofatumumab, Kesimpta | Novartis Pharmaceuticals | Multiple Sclerosis | 04/23 | 04/23 | | |
| Completed | N/A | 60 | Europe | Natalizumab, Tysabri, BG00002 | Biogen | Relapsing Remitting Multiple Sclerosis | 10/23 | 10/23 | | |
NCT04565431: Examining Effects of Tysabri on Cognitive Fatigue Using fMRI |
|
|
| Recruiting | N/A | 25 | US | Tysabri | Kessler Foundation, St. Barnabas Medical Center | Multiple Sclerosis, Relapsing-Remitting | 12/24 | 12/24 | | |
| Completed | N/A | 318 | Europe | Natalizumab | Biogen | Relapsing-Remitting Multiple Sclerosis (RRMS) | 04/24 | 04/24 | | |
| Completed | N/A | 68 | Europe, RoW | Questionnaire | University Hospital, Bordeaux, Biogen | Multiple Sclerosis | 12/23 | 12/23 | | |
NCT03399981: Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries |
|
|
| Completed | N/A | 80327 | US | Tysabri, Natalizumab BG00002 | Biogen | Progressive Multifocal Leukoencephalopathy | 12/23 | 12/23 | | |
Tys at Home, NCT04777539: Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis |
|
|
| Active, not recruiting | N/A | 279 | Europe | At-home natalizumab treated MS patient | Nantes University Hospital, Rennes University Hospital | Multiple Sclerosis (MS) | 11/24 | 05/25 | | |
SATURATE-MS, NCT05701423: A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants |
|
|
| Terminated | N/A | 34 | Europe | Natalizumab, Tysabri | Biogen | Multiple Sclerosis | 07/24 | 07/24 | | |
NCT05925049: A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS) |
|
|
| Active, not recruiting | N/A | 400 | US | Natalizumab, Tysabri | Biogen | Multiple Sclerosis | 12/25 | 12/25 | | |
NCT05236777: TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants |
|
|
| Recruiting | N/A | 600 | RoW | Natalizumab, Tysabri | Biogen, ReMuS Registry | Multiple Sclerosis | 04/25 | 04/25 | | |
| Recruiting | N/A | 900 | US | Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso | Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society | Multiple Sclerosis, Relapsing-Remitting | 08/25 | 08/25 | | |
| Completed | N/A | 6620 | Europe, Canada, RoW | Tysabri, BG00002, natalizumab | Biogen | Relapsing-Remitting Multiple Sclerosis | 11/23 | 11/23 | | |
|
|
|
|
|
|
|
|
|
NCT05688436: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate |
|
|
| Recruiting | N/A | 1178 | US | Diroximel Fumarate, VUMERITY, BIIB098, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Tysabri, BG00002, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod | Biogen | Multiple Sclerosis | 01/31 | 01/31 | | |
NCT05658497: Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) |
|
|
| Recruiting | N/A | 908 | Europe, US | Diroximel Fumarate, VUMERITY, BIIB098, Avonex, BG9418, interferon beta-1a, Tysabri, Natalizumab, BG00002, Dimethyl Fumarate, Tecfidera, DMF, BG00012 | Biogen | Multiple Sclerosis | 07/32 | 07/32 | | |